Sandoz has entered into a binding agreement to acquire Aspen Pharmacare’s Japanese business for up to €400m ($441m). The two companies expect to complete the cash transaction during the first half of 2020, subject to satisfying certain conditions that include antitrust clearance from Japan’s Fair Trade Commission and the consent of lenders in terms of Aspen’s syndicated debt facilities.
For Sandoz, gaining Aspen’s portfolio of largely mature brands will reinforce its position in the hospital sector of Japan’s generics...
